ArriVent BioPharma Common Stock Statistics
Share Statistics
ArriVent BioPharma Common Stock has 34.02M
shares outstanding. The number of shares has increased by null%
in one year.
| Shares Outstanding | 34.02M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | 82.31% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 4,837 |
| FTD / Avg. Volume | 2.37% |
Short Selling Information
The latest short interest is 5.36M, so 15.76% of the outstanding
shares have been sold short.
| Short Interest | 5.36M |
| Short % of Shares Out | 15.76% |
| Short % of Float | 22.07% |
| Short Ratio (days to cover) | 17.11 |
Valuation Ratios
The PE ratio is -10.42 and the forward
PE ratio is -6.08.
ArriVent BioPharma Common Stock's PEG ratio is
-0.58.
| PE Ratio | -10.42 |
| Forward PE | -6.08 |
| PS Ratio | 0 |
| Forward PS | 2.5 |
| PB Ratio | 3.25 |
| P/FCF Ratio | -11.94 |
| PEG Ratio | -0.58 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for ArriVent BioPharma Common Stock.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 13.14,
with a Debt / Equity ratio of 0.
| Current Ratio | 13.14 |
| Quick Ratio | 13.14 |
| Debt / Equity | 0 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-1,547,846.15 |
| Employee Count | 52 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by 20.53% in the
last 52 weeks. The beta is 1.49, so ArriVent BioPharma Common Stock's
price volatility has been higher than the market average.
| Beta | 1.49 |
| 52-Week Price Change | 20.53% |
| 50-Day Moving Average | 20.22 |
| 200-Day Moving Average | 24.96 |
| Relative Strength Index (RSI) | 56.24 |
| Average Volume (20 Days) | 204,216 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -94.31M |
| Net Income | -80.49M |
| EBITDA | -80.49M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -2.56 |
Full Income StatementBalance Sheet
The company has 74.29M in cash and 176K in
debt, giving a net cash position of 74.12M.
| Cash & Cash Equivalents | 74.29M |
| Total Debt | 176K |
| Net Cash | 74.12M |
| Retained Earnings | -238.33M |
| Total Assets | 274.94M |
| Working Capital | 209.71M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -70.21M
and capital expenditures 0, giving a free cash flow of -70.21M.
| Operating Cash Flow | -70.21M |
| Capital Expenditures | n/a |
| Free Cash Flow | -70.21M |
| FCF Per Share | -2.23 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
